Zealand Pharma appears to have taken a small step forward with a candidate that targets both GLP-1 and GLP-2, an approach that aims to ease side effects seen in many obesity drugs.
In the investigator-led, 54-subject DREAM trial, dapiglutide delivered a low 2.9% weight loss change from baseline in the 4 mg dose (p=0.483), but the 6 mg dose offered a relatively higher 4.3% change (p=0.077) compared with placebo (2.2%) at 12 weeks, the Danish biotech said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.